for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Viewray Inc

VRAY.OQ

Latest Trade

3.41USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

2.76

 - 

10.43

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
3.41
Open
--
Volume
--
3M AVG Volume
43.44
Today's High
--
Today's Low
--
52 Week High
10.43
52 Week Low
2.76
Shares Out (MIL)
98.48
Market Cap (MIL)
352.56
Forward P/E
-2.96
Dividend (Yield %)
--

Next Event

Viewray Inc Annual Shareholders Meeting

Latest Developments

More

ViewRay Reports Q2 Loss Per Share $0.32

Perceptive Advisors Llc Reports 5.1 Percent Passive Stake In Viewray Inc

Viewray Reports Q1 Loss Per Share $0.34

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Viewray Inc

ViewRay Inc. designs, manufactures and markets the ViewRay MRIdian. The MRIdian is a system that integrates high quality radiation therapy with simultaneous magnetic resonance imaging (MRI). It provides two generations of the MRIdian: the first generation MRIdian with Cobalt-60 based radiation beams and the second generation MRIdian Linac, with linear accelerator (linac) based radiation beams. The MRIdian combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients. MRIdian also records the level of radiation dose that the treatment area has received. MRIdian system is comprised of three components: the MRI system, the radiation delivery system and an integrated treatment planning and delivery software. The MRI system is the component of MRIdian that captures soft tissue images of the patient’s body. Its MRI system captures and displays live images in one plane, four times per second or in three planes, two times per second.

Industry

Medical Equipment & Supplies

Contact Info

2 Thermo Fisher Way

+1.440.7033210

http://www.viewray.com/

Executive Leadership

Daniel Jeffrey Moore

Independent Chairman of the Board

Scott William Drake

President, Chief Executive Officer, Director

Ajay Bansal

Chief Financial Officer

Shahriar Matin

Chief Operating Officer

Robert M. Fuchs

Chief Human Resource Officer

Key Stats

1.70 mean rating - 10 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.1K

2019(E)

0.1K
EPS (USD)

2016

-1.260

2017

-1.230

2018

-0.980

2019(E)

-1.208
Price To Earnings (TTM)
--
Price To Sales (TTM)
3.97
Price To Book (MRQ)
2.86
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
45.11
LT Debt To Equity (MRQ)
45.11
Return on Investment (TTM)
-70.33
Return on Equity (TTM)
-53.85

Latest News

BRIEF-ViewRay Announces $59 Mln Equity Financing

* VIEWRAY -ENTERED INTO AGREEMENT TO SELL COMMON STOCK AND WARRANTS TO AFFILIATE OF FOSUN INTERNATIONAL IN DIRECT REGISTERED OFFERING FOR $59.1 MILLION

BRIEF-Viewray Announces Preliminary Q4 And Fiscal Year 2017 Results

* VIEWRAY ANNOUNCES PRELIMINARY FOURTH QUARTER AND FISCAL YEAR 2017 RESULTS

BRIEF-Viewray Files For Resale By Selling Stockholders Of 6.7 Million Shares Of Co

* VIEWRAY INC FILES FOR RESALE BY SELLING STOCKHOLDERS OF 6.7 MILLION SHARES OF CO - SEC FILING Source text :[http://bit.ly/2Bp8yIs] Further company coverage:

BRIEF-ViewRay Q3 loss per share $0.19

* Q3 earnings per share view $-0.12 -- Thomson Reuters I/B/E/S

BRIEF-‍Fosun International Ltd reports a 9.91 pct passive stake in Viewray Inc

* Fosun International Ltd reports a 9.91 percent passive stake in Viewray Inc as of Oct 24, 2017 - SEC filing Source text: (http://bit.ly/2xTl0hH) Further company coverage:

BRIEF-Viewray's unit enters into amendment no. 3 to term loan agreement​

* On October 9, unit of co entered into amendment no. 3 to term loan agreement - SEC filing

BRIEF-ViewRay launches clinical trial for pancreatic cancer using MRIdian System

* ViewRay launches clinical trial following compelling early pancreatic cancer data with MRidian System Source text for Eikon: Further company coverage:

BRIEF-Viewray Q2 loss per share $0.15

* Q2 earnings per share view $-0.24 -- Thomson Reuters I/B/E/S

BRIEF-Viewray Q1 loss per share $0.54

* Q1 earnings per share view $-0.22 -- Thomson Reuters I/B/E/S

BRIEF-Viewray files for mixed shelf of up to $100 mln

* Viewray Inc files for mixed shelf of up to $100 million - sec filing Source text: (http://bit.ly/2od3BQd) Further company coverage:

BRIEF-Viewray announces $15 mln capacity expansion of term loan agreement

* Viewray announces $15.0 million capacity expansion of its term loan agreement

BRIEF-Viewray files for offering, resale by selling stockholders of 10.3 mln shares

* Files for offering and resale by the selling stockholders of 10.3 million shares of common stock - sec filing Source text for Eikon: Further company coverage:

BRIEF-Viewray Q4 loss per share $0.25

* Viewray reports fourth quarter and full year 2016 financial results

BRIEF-ViewRay receives FDA 510(k) clearance for MRIdian Linac

* Total backlog of $133.2 million as of December 31, 2016, representing 23 signed sales contracts

BRIEF-Viewray files for mixed shelf of up to $75.0 Mln

* Files for mixed shelf of up to $75.0 million - sec filing Source text : http://bit.ly/2jMGg4d Further company coverage:

BRIEF-Puissance Capital Management LP reports 13.1 pct stake in Viewray - SEC filing

* Reports 13.1 percent stake in Viewray Inc as of Jan 18 - SEC filing Source text : (http://bit.ly/2k15n3C) Further company coverage:

BRIEF-Orbimed Advisors Llc reports 18.8 pct stake in Viewray Inc

* Orbimed Advisors Llc reports 18.8 percent stake in Viewray Inc as of January 18, 2017 versus 22.6 percent stake as of August 22, 2016 - SEC filing Source text: [http://bit.ly/2kbwQkd] Further company coverage:

BRIEF-ViewRay receives CE mark approval for MRIdian Linac system

* Company has also submitted its 510(K) application for MRIdian Linac technology in United States.

BRIEF-ViewRay wins China FDA approval for its MRIdian system

* Says has received china food and drug administration approval for its mridian system Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up